A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

NCT06062420 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

316

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms, Head and Neck

Interventions

DRUG: Dostarlimab
DRUG: Belrestotug
DRUG: Nelistotug
DRUG: Remzistotug

Sponsor

GlaxoSmithKline

Collaborators

[object Object]